Revision as of 01:08, 14 May 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

5 regimens on this page 5 variants on this page

Untreated

CHOP-14

back to top

CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone

Synonyms: CHOP-DI, I-CHOP

Structured Concept: none

Regimen

Study	Evidence	Comparator
Tsukasaki et al. 2007 (JCOG 9801)	Phase III	mLSG15

Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
Vincristine (Oncovin) 1.4 mg/m2 (max dose 2 mg) IV once on day 1
Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5

Supportive medications:

Filgrastim (Neupogen) given once neutrophil count decreased to less than 1 × 10^9/L and continued once per day until count increased to greater than 5 x 10^9/L

14-day cycle x 8 cycles

Intrathecal component

Intrathecal triple-therapy was given during recovery phase of cycles 1, 3, and 5 after platelet count was > 70k.

3 doses, total

References

Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article contains verified protocol PubMed

LSG15

back to top

Regimen

Study	Evidence
Yamada et al. 2001 (JCOG 9303)	Phase II

Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by mLSG15.

Chemotherapy

Vincristine (Oncovin) 1 mg/m2 (maximum dose = 2 mg) IV once on day 1
Cyclophosphamide (Cytoxan) 350 mg/m2 IV once on day 1
Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1, 8, 15 to 17
Ranimustine (Cymerin) 60 mg/m2 IV once on day 8
Vindesine (Eldisine) 2.4 mg/m2 IV once on day 15
Etoposide (Vepesid) 100 mg/m2 IV once per day on days 15 to 17
Carboplatin (Paraplatin) 250 mg/m2 IV once on day 15

28-day cycle x 7 cycles

References

Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. link to original article [PubMed http://www.ncbi.nlm.nih.gov/pubmed/11380402]

mLSG15

back to top

Regimen

Study	Evidence	Comparator
Tsukasaki et al. 2007 (JCOG 9801)	Phase III	CHOP-14
Ishida et al. 2015	Randomized Phase II	mLSG15 & mogamulizumab

Ranimustine is not available in the United States and is approved only in Japan.

Chemotherapy

Vincristine (Oncovin) 1 mg/m2 (maximum dose = 2 mg) IV once on day 1
Cyclophosphamide (Cytoxan) 350 mg/m2 IV once on day 1
Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1, 8, 15 to 17
Ranimustine (Cymerin) 60 mg/m2 IV once on day 8
Vindesine (Eldisine) 2.4 mg/m2 IV once on day 15
Etoposide (Vepesid) 100 mg/m2 IV once per day on days 15 to 17
Carboplatin (Paraplatin) 250 mg/m2 IV once on day 15

28-day cycle x 6 cycles

CNS prophylaxis

Cytarabine (Cytosar) 40 mg mixed with Methotrexate (MTX) 15 mg and Prednisone (Sterapred) 10 mg IT

Given after cycles 1, 3, and 5 after platelets > 70 × 10⁹/L and within 2 days before the next cycle

References

Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article PubMed
Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672-82. Epub 2015 Mar 2. link to original article PubMed

@@ Line 62: / Line 62: @@
 # Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. [http://jco.ascopubs.org/content/25/34/5458.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17968021 PubMed]
-==mLSG15 {{#subobject:832886|Regimen=1}}==
+==LSG15 {{#subobject:96c8e2|Regimen=1}}==
 {| class="wikitable" style="float:right; margin-left: 5px;"
 |-
@@ Line 68: / Line 68: @@
 |}
-===Regimen {{#subobject:1dc050|Variant=1}}===
+===Regimen {{#subobject:2fae5f|Variant=1}}===
 {| border="1" style="text-align:center;" !align="left"
 |'''Study'''
 |[[Levels_of_Evidence#Evidence|'''Evidence''']]
-|'''Comparator'''
 |-
 |[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02737.x/full Yamada et al. 2001 (JCOG 9303)]
@@ Line 81: / Line 80: @@
 border-width:2px;
 border-style:solid;">Phase II</span>
-|
 |-
-!colspan="4" align="center"|
+|}
+''Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by [[#mLSG15|mLSG15]].''
+====Chemotherapy====
+*[[Vincristine (Oncovin)]] 1 mg/m2 (maximum dose = 2 mg) IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 350 mg/m2 IV once on day 1
+*[[Doxorubicin (Adriamycin)]] 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
+*[[Prednisone (Sterapred)]] 40 mg/m2 PO once per day on days 1, 8, 15 to 17
+*[[Ranimustine (Cymerin)]] 60 mg/m2 IV once on day 8
+*[[Vindesine (Eldisine)]] 2.4 mg/m2 IV once on day 15
+*[[Etoposide (Vepesid)]] 100 mg/m2 IV once per day on days 15 to 17
+*[[Carboplatin (Paraplatin)]] 250 mg/m2 IV once on day 15
+'''28-day cycle x 7 cycles'''
+===References===
+# Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02737.x/full link to original article] [PubMed http://www.ncbi.nlm.nih.gov/pubmed/11380402]
+==mLSG15 {{#subobject:832886|Regimen=1}}==
+{| class="wikitable" style="float:right; margin-left: 5px;"
+|-
+|[[#toc|back to top]]
+|}
+===Regimen {{#subobject:1dc050|Variant=1}}===
+{| border="1" style="text-align:center;" !align="left"
+|'''Study'''
+|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+|'''Comparator'''
 |-
 |[http://jco.ascopubs.org/content/25/34/5458.long Tsukasaki et al. 2007 (JCOG 9801)]
@@ Line 93: / Line 118: @@
 border-style:solid;">Phase III</span>
 |[[Adult_T-cell_leukemia-lymphoma#CHOP-14|CHOP-14]]
-|-
-!colspan="4" align="center"|
 |-
 |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13338/full Ishida et al. 2015]
@@ Line 106: / Line 129: @@
 |-
 |}
-To be completed
+''Ranimustine is not available in the United States and is approved only in Japan.''
+====Chemotherapy====
+*[[Vincristine (Oncovin)]] 1 mg/m2 (maximum dose = 2 mg) IV once on day 1
+*[[Cyclophosphamide (Cytoxan)]] 350 mg/m2 IV once on day 1
+*[[Doxorubicin (Adriamycin)]] 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
+*[[Prednisone (Sterapred)]] 40 mg/m2 PO once per day on days 1, 8, 15 to 17
+*[[Ranimustine (Cymerin)]] 60 mg/m2 IV once on day 8
+*[[Vindesine (Eldisine)]] 2.4 mg/m2 IV once on day 15
+*[[Etoposide (Vepesid)]] 100 mg/m2 IV once per day on days 15 to 17
+*[[Carboplatin (Paraplatin)]] 250 mg/m2 IV once on day 15
+'''28-day cycle x 6 cycles'''
+====CNS prophylaxis====
+*[[Cytarabine (Cytosar)]] 40 mg mixed with [[Methotrexate (MTX)]] 15 mg and [[Prednisone (Sterapred)]] 10 mg IT
+'''Given after cycles 1, 3, and 5 after platelets > 70 × 10<sup>9</sup>/L and within 2 days before the next cycle'''
 ===References===
-# Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02737.x/full link to original article] [PubMed http://www.ncbi.nlm.nih.gov/pubmed/11380402]
 <!-- Presented in part at the 47th Annual Meeting of the American Society of Hematology, December 10-13, 2005, Atlanta, GA. -->
 # Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. [http://jco.ascopubs.org/content/25/34/5458.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/17968021 PubMed]
 # Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672-82. Epub 2015 Mar 2. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13338/full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25733162 PubMed]

Difference between revisions of "Adult T-cell leukemia-lymphoma"

Revision as of 01:08, 14 May 2016

Contents

Untreated

CHOP-14

Regimen

Intrathecal component

References

LSG15

Regimen

Chemotherapy

References

mLSG15

Regimen

Chemotherapy

CNS prophylaxis

References

Navigation menu

Search